What is HC Wainwright’s Forecast for IOVA Q1 Earnings?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Iovance Biotherapeutics in a research report issued to clients and investors on Friday, February 28th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will earn ($0.23) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q4 2025 earnings at ($0.13) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.26). The business had revenue of $73.69 million for the quarter, compared to the consensus estimate of $72.17 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%.

A number of other equities research analysts also recently weighed in on the company. Robert W. Baird dropped their target price on Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, February 28th. The Goldman Sachs Group reduced their target price on Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Monday. Truist Financial cut their target price on shares of Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday. Piper Sandler dropped their price target on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating on the stock in a research report on Friday, February 28th. Finally, Chardan Capital lowered their target price on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Monday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.25.

Iovance Biotherapeutics Price Performance

Shares of Iovance Biotherapeutics stock opened at $3.92 on Monday. Iovance Biotherapeutics has a 1 year low of $3.62 and a 1 year high of $17.64. The business has a fifty day simple moving average of $6.14 and a two-hundred day simple moving average of $8.50. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -2.63 and a beta of 0.53.

Hedge Funds Weigh In On Iovance Biotherapeutics

Large investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in Iovance Biotherapeutics in the 4th quarter worth about $515,000. Jennison Associates LLC bought a new stake in Iovance Biotherapeutics in the fourth quarter worth $493,000. Barclays PLC boosted its position in Iovance Biotherapeutics by 118.8% during the third quarter. Barclays PLC now owns 604,584 shares of the biotechnology company’s stock valued at $5,677,000 after buying an additional 328,284 shares during the period. Principal Financial Group Inc. grew its stake in shares of Iovance Biotherapeutics by 59.0% during the third quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock valued at $37,872,000 after buying an additional 1,496,941 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Iovance Biotherapeutics in the third quarter worth about $920,000. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.